24/7 Market News Snapshot 23 June, 2025 – Fractyl Health, Inc. Common Stock (NASDAQ:GUTS)

June 23, 2025

DENVER, Colo., 23 June, 2025 (www.247marketnews.com) – (NASDAQ:GUTS) are discussed in this article.
Fractyl Health, Inc. is witnessing a promising uptick in its stock performance, with shares trading at $2.287, reflecting a substantial increase of 6.87% from the previous close of $2.140. This upward trajectory may be indicative of positive investor sentiment and potential buying pressure, as evidenced by a trading volume of 1.13 million shares. Market observers suggest that these dynamics could signify a strong belief in Fractyl Health’s future prospects within the healthcare sector, warranting scrutiny of key resistance levels and volume trends for ongoing investment decisions.

In parallel to its market performance, Fractyl Health is making pivotal advancements in the field of metabolic disorders through its Rejuva Smart GLP-1 pancreatic gene therapy platform, recently showcased at the American Diabetes Association’s 85th Scientific Sessions. The latest preclinical results reveal that a single dose of Rejuva was well tolerated in healthy animal models, demonstrating effectiveness in preventing both weight gain and hyperglycemia associated with high-fat diets. Specifically, treated subjects exhibited a 20% reduction in body weight and a remarkable 38% decrease in blood glucose levels, while healthy animals maintained baseline weight and experienced an 8% drop in blood glucose.

Dr. Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, expressed optimism about Rejuva’s potential to revolutionize metabolic disease management. The therapy operates uniquely by activating during metabolic stress, offering a more favorable risk-benefit profile compared to traditional chronic GLP-1 therapies by effectively mimicking natural hormone regulation.

Supporting this initiative is a collaborative research team from prestigious institutions, all focused on providing a long-lasting, disease-modifying treatment to combat the increasing prevalence of obesity and type 2 diabetes. With regulatory applications for RJVA-001 in progress, Fractyl anticipates the commencement of clinical trials by 2026, positioning itself as a leader in innovative therapies aimed at restoring metabolic balance.

Related news for (GUTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.